SEC Comment Letter 0000000000-24-011578 to Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Oct. 15, 2024 · CIK: 0002022416 · Accession: 0000000000-24-011578
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282556
Letter
October 15, 2024 Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 2 Ha’ma’ayan Street Modi’in-Maccabim-Reut, Israel 7177871 Re:Silexion Therapeutics Corp Registration Statement on Form S-1 Filed October 9, 2024 File No. 333-282556 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jonathan M. Nathan
Show Raw Text
October 15, 2024
Ilan Hadar
Chief Executive Officer
Silexion Therapeutics Corp
2 Ha’ma’ayan Street
Modi’in-Maccabim-Reut, Israel 7177871
Re:Silexion Therapeutics Corp
Registration Statement on Form S-1
Filed October 9, 2024
File No. 333-282556
Dear Ilan Hadar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jonathan M. Nathan